XML 26 R17.htm IDEA: XBRL DOCUMENT
v3.19.2

Total Operating Expenses | 6 Months Ended
--- | ---
Jun. 30, 2019
Text block [abstract] |
Total Operating Expenses | 12. Total Operating Expenses R&D costs are comprised of allocated employee costs, the costs of materials and laboratory consumables, intellectual property and license costs and allocated other costs. The following table presents a breakdown of operating expenses:
|  | Three months ended June 30, |  |  | Six months ended June 30, |
|  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
|  | (euros in thousands) |
Manufacturing costs |  |  | 450 |  |  |  | 5,580 |  |  |  | 2,325 |  |  |  | 9,858 |
IP and license costs |  |  | 585 |  |  |  | 492 |  |  |  | 876 |  |  |  | 844 |
Personnel related R&D |  |  | 2,470 |  |  |  | 2,107 |  |  |  | 4,510 |  |  |  | 3,808 |
Other R&D costs |  |  | 6,479 |  |  |  | 4,344 |  |  |  | 12,644 |  |  |  | 8,311 |
Total R&D costs |  |  | 9,984 |  |  |  | 12,523 |  |  |  | 20,355 |  |  |  | 22,821 |
Management and administration costs |  |  | 3,119 |  |  |  | 2,639 |  |  |  | 5,055 |  |  |  | 5,491 |
Litigation costs |  |  | 59 |  |  |  | 552 |  |  |  | 123 |  |  |  | 849 |
Other operating expenses |  |  | 3,684 |  |  |  | 2,745 |  |  |  | 7,624 |  |  |  | 5,134 |
Total other expenses |  |  | 3,743 |  |  |  | 3,297 |  |  |  | 7,747 |  |  |  | 5,983 |
Total operating expenses |  |  | 16,846 |  |  |  | 18,459 |  |  |  | 33,157 |  |  |  | 34,295 |
R&D costs were €9.9 million and €20.3 million for the three and six months ended June 30, 2019, respectively, as compared to €12.5 million and €22.8 million for the three and six months ended June 30, 2018, respectively. The decrease in R&D costs is primarily attributable to lower manufacturing costs, primarily for MCLA-128, and MCLA-145, partially offset by higher preclinical costs; and higher R&D headcount and related costs. Other R&D costs consist mainly of laboratory supplies and depreciation expense related to R&D activities, which cannot be specifically allocated to a research project. A breakdown of other R&D costs is presented as follows:
|  | Three months ended June 30, |  |  | Six months ended June 30, |
|  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
|  | (euros in thousands) |
Discovery and preclinical costs |  |  | 2,055 |  |  |  | 1,078 |  |  |  | 4,175 |  |  |  | 1,763 |
Clinical costs |  |  | 3,156 |  |  |  | 1,850 |  |  |  | 6,041 |  |  |  | 4,248 |
Other R&D costs |  |  | 1,268 |  |  |  | 1,416 |  |  |  | 2,428 |  |  |  | 2,300 |
Total other R&D costs |  |  | 6,479 |  |  |  | 4,344 |  |  |  | 12,644 |  |  |  | 8,311 |
Management and administration costs Management and administration costs were €3.1 million and €5.1 million for the three and six months ended June 30, 2019, respectively, as compared to €2.6 million and €5.5 million for the three and six months ended June 30, 2018, respectively. The increase in management and administration costs during the three months ended June 30, 2019 is primarily attributable to higher management and administration headcount and related costs, primarily offset by a decrease in share-based compensation expense. The decrease in management and administration costs during the six months ended June 30, 2019 is primarily attributable to a decrease in share-based compensation expense, partially offset by higher management and administration headcount and related costs. Litigation costs On April 5, 2018, an unnamed third party and Regeneron filed notices of opposition against the Company’s EP 2604625 patent, entitled “Generation of Binding Molecules,” in the European Patent Office. The notices asserted, as applicable, added subject matter, lack of novelty, lack of inventive step, and insufficiency. Regeneron withdrew from this proceeding in January 2019. On August 20, 2018, the Company timely responded to these submissions, and again in April 2019, with proceedings to be ongoing with respect to the unnamed third party. An opposition hearing was held June 2019 during which the patent was revoked. The Company intends to appeal this decision to the Technical Board of Appeals. As this opposition proceeding continues, the Company cannot be certain that the Company will ultimately prevail. The litigation and opposition related costs were €59,000 and €0.1 for the three and six months ended June 30, 2019, respectively, as compared to litigation and opposition costs incurred of €0.6 million and €0.8 million for the three and six months ended June 30, 2018, respectively, and are included in the condensed consolidated statement of profit or loss and comprehensive loss for the period. From time to time, the Company may be involved in various other claims and legal proceedings relating to claims arising out of the Company’s operations. The Company is not currently a party to any other material legal proceedings. Other operating expenses Other operating expenses were €3.6 million and €7.6 million for the three and six months ended June 30, 2019, respectively, as compared to €2.7 million and €5.1 million for the three and six months ended June 30, 2018, respectively. The increase in other operating expenses is primarily attributable to an increase in consultant costs to support accounting operations and facilities-related expenses for the Cambridge, MA facility.

X
- Definition The disclosure of information about operating expenses. + References No definition available. + Details
Name: | mrus_DisclosureOfOperatingExpensesExplanatory
Namespace Prefix: | mrus_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Text Block [abstract] + References No definition available. + Details
Name: | mrus_TextBlockAbstract
Namespace Prefix: | mrus_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration